Lawreen H Connors1, Flora Sam2, Martha Skinner2, Francesco Salinaro2, Fangui Sun2, Frederick L Ruberg2, John L Berk2, David C Seldin2. 1. From Amyloidosis Center (L.H.C., F. Sam, M.S., F. Salinaro, F.L.R., J.L.B., D.C.S.), Department of Pathology and Laboratory Medicine (L.H.C), and Department of Medicine (F. Sam, M.S., F.L.R., J.L.B., D.C.S.), Boston University School of Medicine, MA; Department of Medicine, University of Pavia, Italy (F. Salinaro); and Department of Biostatistics, Boston University School of Public Health, MA (F. Sun). lconnors@bu.edu. 2. From Amyloidosis Center (L.H.C., F. Sam, M.S., F. Salinaro, F.L.R., J.L.B., D.C.S.), Department of Pathology and Laboratory Medicine (L.H.C), and Department of Medicine (F. Sam, M.S., F.L.R., J.L.B., D.C.S.), Boston University School of Medicine, MA; Department of Medicine, University of Pavia, Italy (F. Salinaro); and Department of Biostatistics, Boston University School of Public Health, MA (F. Sun).
Abstract
BACKGROUND: Heart failure caused by wild-type transthyretin amyloidosis (ATTRwt) is an underappreciated cause of morbidity and mortality in the aging population. The aims of this study were to examine features of disease and to characterize outcomes in a large ATTRwt cohort. METHODS AND RESULTS: Over 20 years, 121 patients with ATTRwt were enrolled in a prospective, observational study. Median age at enrollment was 75.6 years (range, 62.6-87.8 years); 97% of patients were white. The median survival, measured from biopsy diagnosis, was 46.69 months (95% confidence interval, 41.95-56.77); 78% of deaths were attributable to cardiac causes. By Kaplan-Meier analysis, 5-year survival was 35.7% (95% confidence interval, 25-46). Impaired functional capacity (mean Vo2max, 13.5 mL·kg(-1)·min(-1)) and atrial fibrillation (67%) were common clinical features. Multivariate predictors of reduced survival were elevated serum brain natriuretic peptide (482 ± 337 pg/mL) and uric acid (8.2 ± 2.6 mg/dL), decreased left ventricular ejection fraction (50% median; range, 10%-70%), and increased relative wall thickness (0.75 ± 0.19). CONCLUSIONS: In this series of patients with biopsy-proven ATTRwt, poor functional capacity and atrial arrhythmias were common clinical features. Elevated brain natriuretic peptide and uric acid, decreased left ventricular ejection fraction, and increased relative wall thickness were associated with limited survival of only 35.7% at 5 years for the group as a whole. These data establish the natural history of ATTRwt, provide statistical basis for the design of future interventional clinical trials, and highlight the need for more sensitive diagnostic tests and disease-specific treatments for this disease.
BACKGROUND:Heart failure caused by wild-type transthyretinamyloidosis (ATTRwt) is an underappreciated cause of morbidity and mortality in the aging population. The aims of this study were to examine features of disease and to characterize outcomes in a large ATTRwt cohort. METHODS AND RESULTS: Over 20 years, 121 patients with ATTRwt were enrolled in a prospective, observational study. Median age at enrollment was 75.6 years (range, 62.6-87.8 years); 97% of patients were white. The median survival, measured from biopsy diagnosis, was 46.69 months (95% confidence interval, 41.95-56.77); 78% of deaths were attributable to cardiac causes. By Kaplan-Meier analysis, 5-year survival was 35.7% (95% confidence interval, 25-46). Impaired functional capacity (mean Vo2max, 13.5 mL·kg(-1)·min(-1)) and atrial fibrillation (67%) were common clinical features. Multivariate predictors of reduced survival were elevated serum brain natriuretic peptide (482 ± 337 pg/mL) and uric acid (8.2 ± 2.6 mg/dL), decreased left ventricular ejection fraction (50% median; range, 10%-70%), and increased relative wall thickness (0.75 ± 0.19). CONCLUSIONS: In this series of patients with biopsy-proven ATTRwt, poor functional capacity and atrial arrhythmias were common clinical features. Elevated brain natriuretic peptide and uric acid, decreased left ventricular ejection fraction, and increased relative wall thickness were associated with limited survival of only 35.7% at 5 years for the group as a whole. These data establish the natural history of ATTRwt, provide statistical basis for the design of future interventional clinical trials, and highlight the need for more sensitive diagnostic tests and disease-specific treatments for this disease.
Authors: Angela Dispenzieri; Morie A Gertz; Robert A Kyle; Martha Q Lacy; Mary F Burritt; Terry M Therneau; Joseph P McConnell; Mark R Litzow; Dennis A Gastineau; Ayalew Tefferi; David J Inwards; Ivana N Micallef; Stephen M Ansell; Luis F Porrata; Michelle A Elliott; William J Hogan; S Vincent Rajkumar; Rafael Fonseca; Philip R Greipp; Thomas E Witzig; John A Lust; Steven R Zeldenrust; Denise S Snow; Susan R Hayman; Christopher G A McGregor; Allan S Jaffe Journal: Blood Date: 2004-03-25 Impact factor: 22.113
Authors: Sherif F Nagueh; Christopher P Appleton; Thierry C Gillebert; Paolo N Marino; Jae K Oh; Otto A Smiseth; Alan D Waggoner; Frank A Flachskampf; Patricia A Pellikka; Arturo Evangelisa Journal: Eur J Echocardiogr Date: 2009-03
Authors: Carl J Lavie; Richard V Milani; Sangeeta B Shah; Yvonne E Gilliland; Jose A Bernal; Homeyar Dinshaw; Hector O Ventura Journal: Ochsner J Date: 2008
Authors: Garvan C Kane; Barry L Karon; Douglas W Mahoney; Margaret M Redfield; Veronique L Roger; John C Burnett; Steven J Jacobsen; Richard J Rodeheffer Journal: JAMA Date: 2011-08-24 Impact factor: 56.272
Authors: Sante D Pierdomenico; Domenico Lapenna; Anna Bucci; Bianca M Manente; Franco Cuccurullo; Andrea Mezzetti Journal: Am J Hypertens Date: 2004-11 Impact factor: 2.689
Authors: Teresa Coelho; David Adams; Ana Silva; Pierre Lozeron; Philip N Hawkins; Timothy Mant; Javier Perez; Joseph Chiesa; Steve Warrington; Elizabeth Tranter; Malathy Munisamy; Rick Falzone; Jamie Harrop; Jeffrey Cehelsky; Brian R Bettencourt; Mary Geissler; James S Butler; Alfica Sehgal; Rachel E Meyers; Qingmin Chen; Todd Borland; Renta M Hutabarat; Valerie A Clausen; Rene Alvarez; Kevin Fitzgerald; Christina Gamba-Vitalo; Saraswathy V Nochur; Akshay K Vaishnaw; Dinah W Y Sah; Jared A Gollob; Ole B Suhr Journal: N Engl J Med Date: 2013-08-29 Impact factor: 91.245
Authors: Marios Arvanitis; Clarissa M Koch; Gloria G Chan; Celia Torres-Arancivia; Michael P LaValley; Daniel R Jacobson; John L Berk; Lawreen H Connors; Frederick L Ruberg Journal: JAMA Cardiol Date: 2017-03-01 Impact factor: 14.676
Authors: Balaji Tamarappoo; Yuka Otaki; Osamu Manabe; Mark Hyun; Stephanie Cantu; Yoav Arnson; Heidi Gransar; Sean W Hayes; John D Friedman; Louise Thomson; Piotr Slomka; Damini Dey; Robert Vescio; Jignesh Patel; Daniel S Berman Journal: J Nucl Cardiol Date: 2019-06-06 Impact factor: 5.952
Authors: Frederick L Ruberg; Martha Grogan; Mazen Hanna; Jeffery W Kelly; Mathew S Maurer Journal: J Am Coll Cardiol Date: 2019-06-11 Impact factor: 24.094
Authors: Pooja Phull; Vaishali Sanchorawala; Lawreen H Connors; Gheorghe Doros; Frederick L Ruberg; John L Berk; Shayna Sarosiek Journal: Amyloid Date: 2018-02-09 Impact factor: 7.141
Authors: Keyur B Shah; Anit K Mankad; Adam Castano; Olakunle O Akinboboye; Phillip B Duncan; Icilma V Fergus; Mathew S Maurer Journal: Circ Heart Fail Date: 2016-06 Impact factor: 8.790
Authors: David L Narotsky; Adam Castano; Jonathan W Weinsaft; Sabahat Bokhari; Mathew S Maurer Journal: Can J Cardiol Date: 2016-05-13 Impact factor: 5.223